Results 131 to 140 of about 2,911,119 (244)

Oxidative stress and XIAP signalling in neuronal cells [PDF]

open access: yes, 2010
Oxidative stress is the result of an imbalance in the cellular pro-/antioxidant homeostasis which leads to the overproduction of reactive oxygen species (ROS).
Kairisalo, Minna
core  

A preexisting rare PIK3CA e545k subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling [PDF]

open access: yes, 2018
Combined MEK and CDK4/6 inhibition (MEKi + CDK4i) has shown promising clinical outcomes in patients with NRAS- mutant melanoma. Here, we interrogated longitudinal biopsies from a patient who initially responded to MEKi + CDK4i therapy but subsequently ...
Amaria, Rodabe N.   +20 more
core   +1 more source

Inhibition of oncogenic transcription factor REL by the natural product derivative calafianin monomer 101 induces proliferation arrest and apoptosis in human B-lymphoma cell lines [PDF]

open access: yes, 2015
Increased activity of transcription factor NF-κB has been implicated in many B-cell lymphomas. We investigated effects of synthetic compound calafianin monomer (CM101) on biochemical and biological properties of NF-κB.
Chennamadhavuni, Spandan   +4 more
core   +2 more sources

Sigma-1 receptor enhances neurite elongation of cerebellar granule neurons via TrkB signaling.

open access: yesPLoS ONE, 2013
Sigma-1 receptor (Sig-1R) is an integral membrane protein predominantly expressed in the endoplasmic reticulum. Sig-1R demonstrates a high affinity to various synthetic compounds including well-known psychotherapeutic drugs in the central nervous system (
Yuriko Kimura   +4 more
doaj   +1 more source

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. [PDF]

open access: yes, 2019
Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer,
Carter, Jennifer L   +4 more
core  

Bone Pain and Muscle Weakness in Cancer Patients [PDF]

open access: yes, 2017
PURPOSE OF REVIEW: In this article, we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancer-induced muscle ...
Koniaris, Leonidas G.   +3 more
core   +1 more source

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene. [PDF]

open access: yesFront Oncol, 2023
Cervi C   +10 more
europepmc   +1 more source

Jefferson Digital Commons quarterly report: January-March 2020 [PDF]

open access: yes, 2020
This quarterly report includes: New Look for the Jefferson Digital Commons Articles COVID-19 Working Papers Educational Materials From the Archives Grand Rounds and Lectures JeffMD Scholarly Inquiry Abstracts Journals and Newsletters Master of Public ...
Copeland, LIBT, James   +2 more
core   +1 more source

Relevance of Neurotrophin Receptors CD271 and TrkC for Prognosis, Migration, and Proliferation in Head and Neck Squamous Cell Carcinoma

open access: yesCells, 2019
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and often has a poor prognosis. The present study investigated the role of the low affinity nerve growth factor receptor CD271 as a putative therapy target in HNSCC ...
Yannick Foerster   +7 more
doaj   +1 more source

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy

open access: yesESMO Gastrointestinal Oncology
Background: Currently, mismatch repair deficient/microsatellite instable (dMMR/MSI) status constitutes a validated predictive marker of response to immune checkpoint inhibitors (ICIs) in patients with metastatic colorectal cancer (mCRC).
M. Svrcek   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy